The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 35 results
September 2022
-
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹
Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September… -
Media Release
Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer
Novel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…
June 2022
-
Media Release
Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians
The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval… -
Media Release
Health Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8,…
October 2021
-
Media Release
Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)
In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining… -
Media Release
Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is…